Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
NEW YORK, Aug. 21, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Foundation Medicine, Inc. ("Foundation") (NASDAQ:FMI) securities between February 26, 2014 and November 3, 2015.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/foundation-medicine-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose material information regarding: (1) the reimbursement process and likelihood of coverage for Foundation’s tumor tests by Medicare; and (2) the Company’s financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.
On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it had claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company slashed its 2015 financial guidance, which, unbeknownst to investors, was based on an assumption that Medicare approval was going to be obtained in 2015. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015. Following this disclosure, the price of Foundation common stock fell to a close of $17.31 per share on November 4, 2015.
If you suffered a loss in Foundation you have until September 26, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/foundation-medicine-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
